Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 11/20 | 0.45 |
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | SIK1 | P57059 | 1/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15799597 | 0.96 | TNIK (0.45) | TNIKPAK1PAK4PDPK1JAK1 | |
| SCHEMBL21676912 | 0.95 | TNIK (0.46) | TNIKPAK1PAK4PDPK1JAK1 | |
| SCHEMBL15799549 | 0.93 | TNIK (0.49) | TNIKPAK1PAK4PDPK1JAK1 | |
| SCHEMBL15799697 | 0.89 | TNIK (0.52) | TNIKPAK1PAK4PDPK1SIK1 | |
| SCHEMBL15799554 | 0.85 | PAK1 (0.61) | PAK1PAK4PDPK1SIK1SIK3 | |
| SCHEMBL15799310 | 0.85 | MAP3K9 (0.46) | TNIKPAK1PAK4PDPK1SIK1 | |
| SCHEMBL21676928 | 0.84 | JAK1 (0.38) | TNIKJAK1PIK3CA | |
| SCHEMBL15805229 | 0.83 | SIK1 (0.44) | TNIKPAK1PAK4SIK1SIK3 | |
| SCHEMBL17636826 | 0.83 | PAK1 (0.46) | PAK1PAK4PDPK1SIK1SIK3 | |
| SCHEMBL15805266 | 0.79 | MAP4K1 (0.49) | TNIKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931722-B1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2931722-B1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2931722-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | Arrien Pharmaeuticals LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014093383-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093383-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | TNIK 113/4885PAK1 273/4885PAK4 355/4885 |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | TNIK 113/4885PAK1 273/4885PAK4 355/4885 |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | TNIK 107/4885PAK1 186/4885PAK4 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.